Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC
March 7th 2020Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).
Read More
Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer
May 4th 2019Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.
Read More
Dr. Grivas on Immunotherapy in Platinum-Refractory Metastatic Bladder Cancer
March 19th 2019Petros Grivas, MD, PhD, director of Genitourinary Cancers Program and associate professor of Oncology, University of Washington, medical oncologist, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with metastatic platinum-refractory bladder cancer.
Read More
Dr. Grivas on Bladder Preservation in Localized Bladder Cancer
March 9th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.
Read More